Metabolic dysfunction-associated steatohepatitis (MASH) is often referred to as a “silent disease,” as it typically shows no signs of symptoms in early stages. But it can come with certain ...

Nonalcoholic steatohepatitis (NASH) is the progressive form of liver injury that carries a risk for progressive fibrosis, cirrhosis, and end-stage liver disease. Hepatocellular carcinoma (HCC ...

MASH, which was previously known as non–alcohol related steatohepatitis (NASH), is often asymptomatic or leads to nonspecific symptoms, making progression to more severe stages of liver disease ...

But one risk you may not be as familiar with is metabolic dysfunction–associated steatohepatitis (MASH). MASH is a type of liver inflammation and damage caused by a buildup of fat in the liver.

Non-alcoholic steatohepatitis (NASH) is a condition characterized by accumulation of fat, inflammation and injury in liver cells in people who consume little or no alcohol. It is the progressive ...

PF-07853578 is under clinical development by Pfizer and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to GlobalData, Phase I drugs for Metabolic ...

In 2023, three large multinational liver associations proposed that metabolic dysfunction-associated steatotic liver disease (MASLD) should replace the term NAFLD; the name chosen to replace ...

Fewer than half of the general practitioner training spots in the ACT and the region west of it have been filled as the territory struggles with a GP shortage.